EP Patent

EP3023421A1 — Crystalline forms of afatinib dimaleate

Assigned to Sandoz AG · Expires 2016-05-25 · 10y expired

What this patent protects

A crystalline hydrate form of afatinib dimaleate of formula (I) having an X-ray powder diffraction pattern comprising reflections at at least four 2-theta values of (3.9 ± 0.2) °, (6.3 ± 0.2) °, (7.9 ± 0.2) °, (13.4 ± 0.2) °, (15.1 ± 0.2) °, (25.4 ± 0.2) °, when measured at a tem…

USPTO Abstract

A crystalline hydrate form of afatinib dimaleate of formula (I) having an X-ray powder diffraction pattern comprising reflections at at least four 2-theta values of (3.9 ± 0.2) °, (6.3 ± 0.2) °, (7.9 ± 0.2) °, (13.4 ± 0.2) °, (15.1 ± 0.2) °, (25.4 ± 0.2) °, when measured at a temperature in the range of from 15 to 25 °C with Cu-Kalpha 1,2 radiation having a wavelength of 0.15419 nm.

Drugs covered by this patent

Patent Metadata

Patent number
EP3023421A1
Jurisdiction
EP
Classification
—
Expires
2016-05-25
Drug substance claim
No
Drug product claim
No
Assignee
Sandoz AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.